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Objective: An underlying abnormality in collagen turnover is implied in the occurrence of complications
and recurrences after mesh augmented pelvic floor repair surgeries. Ascorbic acid is a potent stimulant of
collagen synthesis. The aim of this study is to produce ascorbic acid releasing poly-lactic acid (PLA) scaf-
folds and evaluate them for their effects on extracellular matrix production and the strength of the mate-
rials.
Materials and methods: Scaffolds which contained either L-ascorbic acid (AA) and Ascorbate-2-Phosphate
(A2P) were produced with emulsion electrospinning. The release of both drugs was measured by UV
spectrophotometry. Human dermal fibroblasts were seeded on scaffolds and cultured for 2 weeks. Cell
attachment, viability and total collagen production were evaluated as well as mechanical properties.
Results: No significant differences were observed between AA, A2P, Vehicle and PLA scaffolds in terms of
fibre diameter and pore size. The encapsulation efficiency and successful release of both AA and A2P were
demonstrated. Both AA and A2P containing scaffolds were significantly more hydrophilic and stronger in
both dry and wet states compared to PLA scaffolds. Fibroblasts produced more collagen on scaffolds con-
taining either AA or A2P compared to cells grown on control scaffolds.
Conclusion: This study is the first to directly compare the two ascorbic acid derivatives in a tissue engi-
neered scaffold and shows that both AA and A2P releasing electrospun PLA scaffolds increased collagen
production of fibroblasts to similar extents but AA scaffolds seemed to be more hydrophilic and stronger
compared to A2P scaffolds.
Statement of significance
Mesh augmented surgical repair of the pelvic floor currently relies on non-degradable materials which
results in severe complications in some patients. There is an unmet and urgent need for better pelvic floor
repair materials. Our current understanding suggests that the ideal material should be able to better inte-
grate into sites of implantation both biologically and mechanically.
The impact of vitamin C on extracellular matrix production is well established but we in this study have
undertaken a critical comparison of two derivatives of vitamin C as they are released from a biodegrad-
able scaffold. This strategy proved to be equally useful with both derivatives in terms of new tissue pro-
duction yet we observed significant differences in mechanical properties of these biomaterials.
 2015 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Stress urinary incontinence (SUI) and pelvic organ prolapse
(POP) are two major public health issues that can affect the phys-
ical, social and psychological wellbeing of affected women, usuallyaged >40 years [1,2]. Surgical treatment of both conditions often
involves implantation of biomaterials to provide support. Although
there is a reasonable initial success rate, 20–30% of women
will subsequently require re-operation due to complications or
recurrence [3,4]. The complications related to synthetic
non-absorbable mesh implants are particularly concerning for both
patients and physicians [5,6]. Tissue engineering has potential to
overcome such complications through the use of degradable
synthetic matrices with appropriate strength and elasticity that
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and tissue remodelling.
Healthy pelvic floor connective tissues are thought to be in a
state of continuous remodelling involving the synthesis and degra-
dation of collagen and other ECM components [7]. Abnormalities in
this degradation-synthesis equilibrium are not only implicated in
the pathophysiology of pelvic floor defects but may also put any
repair at risk of failure as the underlying primary abnormality in
collagen turnover persists. Degradation of collagen is mediated
by a family of matrix metalloproteinases (MMP), whose activity
is regulated at multiple levels including synthesis, activation, activ-
ity inhibition (tissue MMP inhibitors) and synthesis of collagen
involves a cascade of post-translational modification reactions
leading to a mature, high tensile strength support structure.
Elevated MMP and reduced MMP inhibitor levels were found in
paravaginal tissues of women with urinary incontinence [8] and
also reduced collagen content was evident in endopelvic fascia of
women with SUI and POP compared to healthy women [9,10]. Thus
defective/decreased collagen synthesis is a part of the disease
process in women with SUI and/or POP and incorporation of stim-
ulants of collagen synthesis into biomaterials could be a reasonable
strategy in pelvic floor tissue engineering.
Ascorbic acid plays a crucial role in synthesis and post-
translational modification of collagen. This is widely studied and
thought to occur at multiple levels: [1] acting as a co-factor for
the enzyme prolyl hydroxylase which is responsible for crosslink-
ing of collagen fibrils thus forming the triple helix structure [11],
[2] stimulating collagen gene expression via malondialdehyde
[12] and [3] activation of collagen gene transcription and stabiliza-
tion of procollagen mRNA [13,14]. Also ascorbic acid is a major
antioxidant in human blood at concentrations of 40–80 lM. Safe
intravenous administrations up to a final plasma concentration of
5 mM in cancer patients have been reported [15]. The toxic con-
centrations in culture conditions are consistently reported to be
>0.5 mM [16]. The use of L-ascorbic acid (AA), the naturally occur-
ring and metabolically active form of ascorbic acid in humans, to
increase collagen production of fibroblasts in vitro dates back to
1970s [17]. Its use is limited by its low chemical stability in aerobic
culture conditions [18]. Thus a variety of AA derivatives have been
produced to increase its stability (e.g. Ascorbate-2-Phosphate
[A2P], Na salt of ascorbate). A2P has been the most widely used
synthetic form of AA in cell culture since Hata and Senoo proved
the efficacy of the long acting and stable A2P [19,20]. There have
been a few direct comparisons of AA analogues in cultured fibrob-
lasts [21,22].
Electrospinning is a widely used technique in tissue engineering
that produces scaffolds with micro/nano sized fibres while allow-
ing purposeful modification of the 3D structure [23]. Also electro-
spun PLA scaffolds were shown to have mechanical properties
close to those of healthy paravaginal tissue [24] while showing
successful integration into native tissues in the short term [25].
Emulsion electrospinning is a modification of this technique to
achieve successful incorporation of hydrophilic substances, such
as AA, in the centre of hydrophobic polymer fibres resulting in a
core–shell morphology that enables a sustained release of the
hydrophilic content [26,27]. Thus the emulsion electrospun mats
can serve as both vehicles to deliver bioactive factors and tissue
scaffolds to provide structural support [28]. Previously successful
encapsulation of vascular endothelial growth factors [29],
Rhodamine B [30] and human nerve growth factor [31] into
emulsion electrospun fibres has been demonstrated.
The aims of this study were to construct electrospun PLA scaf-
folds that are able to release the two most commonly used ascorbic
acid derivatives (AA and A2P), to evaluate the comparative effec-
tives of the two in terms of collagen production and finally toassess the impact of the AA and A2P on the mechanical properties
of the electrospun scaffolds.
2. Materials and methods
2.1. Scaffold synthesis and characterisation
2.1.1. Preparation of emulsions
PLA polymer (Sigma–Aldrich) was dissolved 10% w/v in dichlor-
omethane (DCM). Fifty microlitre of Span80 (Sigma–Aldrich) was
added to the polymer solution and stirred at 250 rpm for 10 min.
L-ascorbic acid (Sigma–Aldrich) and L-ascorbic acid 2-phosphate
(SigmaLAldrich) were dissolved in distiled water and a total volume
of 500 ll solution was added drop wise to the PLA-Span80 solution
while stirring 1000 rpm with magnets for 15 min (Fig. 1), the final
concentration being 0.0001, 0.001 and 0.01 g of either AA or A2P
per gram of PLA. Unless stated otherwise, the medium concentra-
tion (0.001 g of AA and A2P per gram of PLA) was used in experi-
ments. A control emulsion electrospun scaffold containing only
500 ll dH2O (Vehicle scaffolds), without AA or A2P was also
included together with a PLA only electrospun scaffold. All emul-
sions were freshly made and electro spun immediately.
2.1.2. Electrospinning conditions
The emulsions were loaded into 5 mL syringes with blunt
tipped stainless steel needles. The emulsions were delivered at a
constant feed rate of 40 ll/min using a programmable syringe
pump (Aladdin 1000) and were electrospun horizontally with an
accelerating voltage of 15 kV supplied by a high voltage power
supply (Brandenburg, Alpha series III, UK). Fibrous mats were col-
lected on aluminium foil sheets wrapped around an earthed alu-
minium rotating collector (rotating at 300 rpm) 15 cm from the
tip of the needle. Scaffolds were produced and left to dry for 1 h
in a fume hood.
2.1.3. AA and A2P release profile
All measurements of AA and A2P were performed using a
UV-spectrophotometer (Thermo ScientificTM Evolution 220) at an
absorbance wavelength of 252 nm. A calibration curve was initially
constructed by measuring 8 concentrations of AA and A2P (lowest:
10 nM and highest: 100 lM) prepared in dH2O and PBS, respec-
tively. All solutions were freshly prepared and the absorbances
were immediately measured. The calibration curve was linear with
a correlation coefficient of R2 > 0.999 for both AA and A2P and the
lower limit of detection was 500 nM.
Initially the feasibility of using PBS to demonstrate AA release
was investigated. For this three pieces of AA scaffolds (mean
weight 0.022 ± 0.001 g) were placed into 4 mL of dH2O or PBS. At
2, 4, 6, 24 and 72 h media was removed, absorbance read and the
media was put back into the well. The concentration was deter-
mined using the calibration curve. The release of AA into dH2O
could be demonstrated with small error bars within the first 6 h
of the experiment whereas we were unable to detect any amount
of AA in PBS except at the first 2 h (Fig. 2). This suggested dH2O
as the sole media to study release of AA.
Release of AA and A2P from scaffolds were studied in dH2O and
PBS, respectively. Three pieces of AA and A2P scaffolds (mean
weights: 0.0199 ± 0.002 and 0.0176 ± 0.002, respectively) were
placed in 4 mL media and were kept in a dry incubator at 37 C.
A vehicle scaffold was taken as a control. At 2, 4, 6, 8, 10 h and 1,
2, 3, 7, 14, 21 and 28 days a sample was removed from the media,
the absorbance measured and the concentration was determined
with use of the calibration curve. All the media were then dis-
carded and replaced with fresh media. Experiments were repeated
three times.
Fig. 1. Preparation of the emulsions containing AA, A2P or dH2O (Vehicle) and proposed mechanism of how the emulsion electrospinning technique produces a core–shell
morphology of hydrophilic (vitamin C) centre out-layered by the hydrophobic PLA (PLA: polylactic acid, DCM: dichloromethane, AA: ascorbic acid, A2P: Ascorbate-2-
Phosphate, dH2O: distiled water).
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Fig. 2. Comparison of dH2O and PBS as a media to study AA release (A) and the calibration curve of ascorbic acid as studied in dH2O (B).
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within the micro/ nanofibers, an accurately weighed 20 mg piece
of scaffold was dissolved in 10 mL of DCM and 5 mL of distiled
water was then added. After vortexing vigorously for 15 min sam-
ples were left to stand still for an hour to allow phase separation.
One millilitre of clear supernatant was then taken and absorbances
were read at 252 nm for determination of AA and A2P concentra-
tion. The following formula was used to calculate encapsulation
efficiency (%):
ðActual drug content=Theoretical drug contentÞ  100:
where actual drug content is the amount drug extracted from the
scaffold and theoretical drug content is the total quantity of the
drug added while preparing the emulsion for electrospinning.2.1.4. Water uptake measurement
Water uptake by scaffolds was assessed by incubating weighed
1  1 cm pieces of each scaffold in 10 mL of PBS. Six samples for
each group were measured. Scaffolds were incubated at 37 C for
21 days and at days 1, 2, 3, 7, 14 and 21 they were carefully blotted
with filter paper to remove surface water and weighed. Water
uptake of each scaffold was expressed as the percent increase in
weight of the scaffold and calculated with the formula:
ðWeightwet WeightdryÞ=Weightdry  100:2.2. Cell response to scaffolds in 2D and 3D cultures of fibroblasts
2.2.1. Culture conditions of human dermal fibroblasts
Human dermal fibroblasts (HDFs) were isolated from skin
obtained from consenting patients undergoing elective surgical
procedures as described previously [32]. Cells were isolated and
expanded in complete cell culture media consisting of Dulbecco’s
Modified Eagles’s Medium (DMEM) (Biosera, UK) supplemented
with 10% foetal calf serum, 2 mM L-glutamine, and 1% penicillin/
streptomycin. HDFs were incubated at 37 C in the presence of
5% CO2 with fresh media changes every 3–4 days and used
between passages 4–9. Each experiment consists of three sample
wells for each condition and was performed in triplicates.
For 2D experiments a total of 50,000 HDFs were seeded per well
of 12 well plates. Media containing 0, 10, 100, 300 and 600 lM of
AA or A2P were prepared freshly and changed every day or every
3–4 days for 14 days. For experiments with confluent fibroblasts,
supplementation was started after cells were confluent. The results
of collagen production in this section were presented as a percent
(%) increase in collagen production compared to collagen produc-
tion of fibroblasts grown in non-supplemented media. In 3D exper-
iments, 0.79 cm2 scaffolds were kept in 70% ethanol for 10 min
after which a total of 500,000 HDFs were seeded and cultured for
14 days.2.2.2. Assessment of cell viability
Cell metabolic activity was measured by a resazurin assay.
Briefly at 1, 3, 7 and 14 days of culture all media was removed from
culture plates, each well was washed with PBS and 5 mL of
125 ll/mL resazurin in PBS was added. Samples were incubated
for 60 min at 37 C. Then absorbance at 570 nm was measured in
a colourimetric plate reader (Bio-TEK, NorthStar Scientific Ltd,
Leeds, UK). Culture wells without cells or cell free scaffolds in
media were used as reagent blanks. Samples were then washed
of the dye and were fixed with 3.7% formaldehyde. Experiments
were performed 3 times in triplicate.2.2.3. Sirius Red staining for total collagen
Fixed samples were washed with PBS. Two millilitre of Sirius
Red stain (0.1% Direct Red 80 in saturated picric acid, Sigma–
Aldrich) was added to each sample of monolayer cultured fibrob-
lasts or fibroblasts grown on scaffolds. After 16 h, excess stain
was washed off with distiled water until the wash out water ran
clear. Then specimens were dried, weighed and the stain eluted
with 2 mL 0.2 M NaOH:methanol 1:1 for 15 min. The absorbance
was measured at 490 nm. Acellular scaffolds acted as controls for
calculating collagen production. Results were expressed as Sirius
Red stain per gram of PLA.
2.3. SEM
The samples were washed in PBS and fixed in 10% buffered
formaldehyde solution for 10–15 min. A 0.1 M cacodylate buffer
was added and incubated for 20 min, glutaraldehyde in cacody-
late buffer was added to the samples for 30 min. Samples were
then washed twice for 15 min each wash in 0.1 M cacodylate
buffer. Next samples were then incubated for 2 h in osmium
tetraoxide. Samples were then incubated in 0.1 M cacodylate
buffer for 15 min. Following this, samples were incubated in
increasing concentrations of ethanol (75%, 95% and 100%) for
15 min each and were incubated for 30 min in 100% ethanol
dried over anhydrous copper sulphate. Finally the ethanol was
removed and hexamethlydisalazine was added to the samples
for 30 min and the samples were then left to dry overnight
before gold sputtering (Edwards Sputter Coater S150B, Crawley,
UK) and imaged with a Phillips XL-20 scanning electron micro-
scope (Cambridge, UK).
Fibre diameters and pore sizes were quantified from SEM
images of electrospun scaffolds. Each experiment had 3 scaffold
samples. Within each 4 images were selected and 10 fibres and 5
pores per image analysed for fibre diameter and pore size,
respectively. This gave a total of 120 fibres and 60 pores analysed
per scaffold. The software ImageJ (National Institutes of Health)
was used for quantification. Pores were identified as areas of void
space bounded by fibres on all sides at or near the same depth of
field.
2.4. Evaluation of mechanical properties
Mechanical properties of wet and dry scaffolds were evaluated.
Scaffolds were cut into 0.5  1 cm pieces, thickness measured then
clamped into a tensiometer (BOSE Electroforce Test Instruments,
MN) using a 22 N load cell and a ramp test at a rate of 0.5 mm/s.
The first failure point and plateau was used to calculate the ulti-
mate tensile strength (UTS) and the displacement at this point
(strain). The initial linear gradient of a plot of stress versus strain
was taken as the Young’s modulus (E).
Since the water uptake of our scaffolds occurred gradually
the mechanical properties in the wet state were evaluated at
days 3, 7, 14 and 21 after the scaffolds were placed in PBS in
incubator.
2.5. Statistical analysis
Statistical analysis was performed with SPSS v. 17.0. Differ-
ences between group means were analysed with Student’s T test
when the data was normally distributed. Comparisons of more
than 2 groups was performed with Kruskal–Wallis test when
the data did not demonstrate a normal distribution. Correlation
between two continuous variables was assessed by Pearson corre-
lation test. A p value of <0.05 was considered statistically
significant.
Fig. 4. Cumulative release of ascorbic acid (AA) and A2P (Ascorbate-2-Phosphate)
from scaffolds into distiled water (dH2O) and PBS, respectively. Inset shows release
over 28 days [n = 6 for each time point, error bars represent standard error of
mean].
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3.1. Effect of AA and A2P on collagen production of fibroblasts in 2D
Daily supplementation of proliferating fibroblasts with 10, 100,
300 and 600 lM concentrations of either AA or A2P resulted in a
dose dependent increase in collagen production up to a maximum
of 100% by 14 days of culture. Compared to supplementation every
3–4 days, which resulted in a maximum of 50% increase in total
collagen production, daily supplementation of AA at a concentra-
tion of 600 lM and daily supplementation of A2P at concentrations
of 100, 300 and 600 lM resulted in significantly more collagen pro-
duction (Fig. 3). The same experimental design was then tested for
confluent cultures of fibroblasts and a dose dependent increase in
collagen production up to a maximum of 60% at 7 days of culture
was observed with a significantly more collagen production at all
concentrations in the daily supplemented groups (Fig. 3).
3.2. Encapsulation efficiency and release of AA and A2P from emulsion
electrospun scaffolds
The encapsulation efficiencies for AA and A2P were calculated
to be 46.8% (±6.45) and 44.06% (±7.14). The cumulative release of
AA and A2P over 28 days based on the actual drug content are
shown in Fig. 4. A burst release of 77% and 34% within 2 h were
observed for AA and A2P, respectively. Approximately 90% of AA
was released by 10 h and further AA was not detectable after
72 h in dH2O. In the case of A2P, 60% of the drug was gradually
released over 14 days. Our inability to detect the missing 10%
might be due to the oxidation of some of this. Alternatively this
small amount remains within the scaffold.
3.3. Characterisation of scaffolds
3.3.1. SEM
SEM images of the scaffolds are shown in Fig. 5 and these
showed there was no significant difference between the AA, A2P,
Vehicle and PLA scaffolds in terms of fibre diameter and pore size.
The average fibre diameters and pore sizes of AA, A2P, Vehicle andProliferang cells Conﬂuent cells
Fig. 3. Comparison of total collagen production of proliferating and confluent
cultures fibroblasts that were supplemented with AA or A2P either daily or once
every 3–4 days (results are at day 14 of culture for proliferating and at day 7 for
confluent cultures, ⁄p < 0.05 and ⁄⁄p < 0.005, compared to every 3–4 days group).PLA scaffolds were 0.99 (±0.60); 1.04 (±0.56); 1.11 (±0.63) and 1.06
(±0.72) lm and 5.66 (±3.18); 5.76 (±2.76); 5.47 (±3.52) and 5.65
(±4.61) lm, respectively.
3.3.2. Water uptake
All the emulsion electrospun scaffolds absorbed water gradually
over several days (Fig. 6A). The water uptake of AA, A2P and Vehi-
cle scaffolds was significantly higher than that of pure electrospun
PLA scaffolds. The water uptake (% increase in weight) of scaffolds
containing AA were significantly higher in the first 7 days com-
pared to vehicle scaffolds [355.84 (±140.36)% vs 274.84
(±108.21)% at day 1, p = 0.005; 407.69 (±62.38)% vs 299.76
(±92.2)% at day 2, p = 0.001; 397.74 (±53.3)% vs 328.76 (±80.31)%
at day 3, p = 0.001 and 363.64 (±45.32)% vs 304.31 (±65.59)% at
day 7, p = 0.001] whereas those of A2P containing scaffolds were
significantly lower at all-time points compared to vehicle scaffolds
[161, 1 (±116.36)% vs 317.55 (±62.25)% at day 14, p = 0.001]
(Fig. 6B). We also noted that the scaffolds became stronger they
more water they absorbed, demonstrated by the correlation
between the percentage increase in weight (PIW) and UTS at max-
imum PIW (Pearson r = 0.66, p < 0.05) (Fig. 6C).
The effect of different concentrations of AA and A2P on water
uptake was also evaluated. No dose dependent change in the water
uptake behaviour of the scaffolds were observed in AA scaffolds
(mean% increase in weight being 350.52 [±192.54], 325.41
[±191.72] and 321.06 [±186.65] for 0.0001, 0.001 and 0.01 g of
AA per gram of PLA concentrations, respectively; Kruskal–Wallis
Chi square = 1.40, p = 0.49) whereas the medium concentration of
A2P scaffolds were slightly more hydrophilic (mean% increase in
weight being 72.84 [±64.24], 174.02 [±153.54] and 79.46 [±84.71]
for 0.0001, 0.001 and 0.01 g of A2P per gram of PLA concentrations,
respectively; Kruskal–Wallis Chi square = 6.69, p = 0.03) (Data not
shown).
3.3.3. Mechanical properties
In their dry state, all AA, A2P and Vehicle scaffolds had approx-
imately 2 times higher UTS, strain and YM values compared to pure
PLA (Fig. 7). No major differences were observed between AA, A2P
and Vehicle scaffolds when dry. When wet the UTS and strain val-
ues of AA and Vehicle scaffolds further increased, whereas the
Young’s modulus were variable. The mechanical properties of
A2P scaffolds did not change significantly when wet compared to
when dry (Fig. 7). The UTS of AA scaffolds were significantly higher
than Vehicle scaffolds only at day 7 (Table 1).
PLA scaﬀold Vehicle scaﬀold AA scaﬀold A2P scaﬀold
Fig. 5. Representative images of scaffolds under scanning electron microscope.
Fig. 6. (A) Representative images of scaffolds at day 1 of water uptake experiment, partial wetting of emulsion electrospun (AA, A2P and Vehicle scaffolds) scaffolds can be
seen and PLA scaffolds are not wet at all, (B) percent increase in weight of the emulsion electrospun scaffolds upon incubation in PBS over days (⁄p < 0.005 compared to
vehicle scaffolds) and (C) correlation of percent increase in weight (PIW) and ultimate tensile strength.
Fig. 7. Dry and wet mechanical properties (The values in the y axis are mean values of days 3, 7, 14 and 21; error bars are 95% CI; n = 61 and n = 240 for dry and wet scaffolds,
respectively).
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centage increase in weight and the UTS of wet scaffolds at day 3, 7,
14 and 21 (Pearson r = 0.64 [p < 0.001], 0.78 [p < 0.001], 0.67
[p < 0.001] and 0.85 [p < 0.001], respectively), the strongest correla-
tion was observed at day 21. The collected data is shown in Fig. 6C.
3.4. Cell viability and collagen production of fibroblasts grown on
scaffolds
The SEM images of scaffolds on which fibroblasts were grown
for 14 days, showed continuous coverage of the scaffold surface
by fibroblasts and extracellular matrix which was more intense
in AA and A2P containing scaffolds (Fig. 8A). A quantitative analysis
of collagen production by Sirius Red staining showed significantly
more collagen production on all concentration of AA and A2P scaf-
folds compared to Vehicle scaffolds (Fig. 8B). The mean corrected
absorbance values (Sirius Red stain/gram of PLA) were 5.44
(±0.50); 5.26 (±0.46); 4.44 (±0.49) and 4.41 (±0.41); 5.32 (±0.55);
5.50 (±0.51) for AA and A2P scaffolds with concentrations of
0.0001, 0.001 and 0.01 g of either AA or A2P per gram of PLA,
respectively. Corresponding values for Vehicle and PLA scaffolds
were 3.86 (±0.43) and 3.39 (±0.43), respectively. Although lower
concentrations of AA and higher concentrations of A2P seemed to
work better, no single concentration of either AA or A2P proved
to be significantly different than other concentrations (Fig. 8B).
Also metabolic activity of human dermal fibroblasts grown on AA
and A2P scaffolds was increased compared to Vehicle scaffolds,
becoming statistically significant after 14 days of culture (Fig. 8C).
4. Discussion
There is a need for new approaches to support weakened tissues
of the pelvic floor for women suffering from POP and SUI. The aim
of this study was to develop and evaluate the use of ascorbic acid
containing scaffolds as an approach to stimulate new tissue pro-
duction for pelvic floor repair while maintaining desirable mechan-
ical properties.
The main findings were that it was possible to introduce either
AA or A2P into biodegradable scaffolds without compromising
mechanical properties, to measure the release of both compounds
into the media and finally that both compounds stimulated colla-
gen production in fibroblasts cultured on the scaffolds.
AA is well documented for its effect in stimulating collagen pro-
duction via several routes and there are various analogues of it, of
which the one used most often in cell culture is A2P because of its
reported greater stability. Accordingly this study began by evaluat-
ing the comparative effectiveness of AA and A2P on collagen pro-
duction of cultured fibroblasts in 2D as we were unable to find
any long-term comparative data on these two in the literature.
The 2D comparison studies were done looking at replacing AATable 1
Mechanical properties at each time point [mean (±SD) values for UTS (Ultimate Tensile Str
scaffolds; ++p < 0.005 +p < 0.05 compared to PLA scaffolds).
DRY (n = 61) WET_day 3 (n = 48) WET_da
UTS Strain YM UTS Strain YM UTS
AA scaffolds 1.39++,⁄⁄ 0.43++ 16.46++,⁄⁄ 2.37++ 0.66++ 20.07++ 2.93++,⁄⁄
(SD) (0.30) (0.06) (5.99) (0.45) (0.15) (7.81) (0.55)
A2P
scaffolds
1.54++ 0.41++ 23.08++ 1.49++,⁄⁄ 0.48 14.76++ 1.28++,⁄⁄
(SD) (0.41) (0.15) (12.07) (0.38) (0.48) (10.81) (0.48)
Vehicle
scaffolds
1.76++ 0.45++ 25.68++ 2.36++ 0.58++ 20.97++ 2.10++
(SD) (0.25) (0.07) (9.03) (0.34) (0.17) (6.42) (0.57)
PLA 0.66 0.22 9.17 0.71 0.40 3.56 0.34
(SD) (0.36) (0.05) (4.20) (0.23) (0.11) (2.12) (0.10)and A2P either daily to mimic the continuous release state that
would overcome the major disadvantages of instability of AA or
every few days. Our findings showed that both AA and A2P
increased collagen production of fibroblasts to a similar extent in
a dose dependent manner.
When AA was given daily (as opposed to being replaced every
3–4 days as would normally occur in routine culture of cells) then
AA was as effective as A2P. Further, there was stimulation of colla-
gen production in both proliferating and confluent fibroblasts and
the concentration which became toxic to cells was in excess of
600 lMwhich confirms previous studies [16]. This data essentially
confirms several previous studies demonstrating increased colla-
gen production when media is supplemented with different
derivatives of AA [16,19,33–36]. Comparing both AA and A2P
under identical conditions with different replacement schedules
(daily versus every 3–4 days) and in proliferative versus confluent
fibroblasts allows us to conclude that both AA and A2P are good
candidates for application in a tissue engineering scaffold.
With emulsion electrospinning we were able to encapsulate
nearly 50% of AA and A2P within the PLA micro/nano fibres. The
initial burst release of AA was higher compared to A2P. Encapsula-
tion efficiency and burst release are two related parameters show-
ing how effectively the drug is captured within the polymer.
Factors such as physical and chemical properties of the polymer
and the drug, polymer–drug interactions and the emulsion condi-
tions are known to affect these parameters [37]. The use of electro-
spun fibres for drug encapsulation and delivery is increasing in
popularity and it can be achieved by emulsion electrospinning
and co-axial electrospinning techniques [38]. Effective drug encap-
sulation (between 17% and 90%) [39–42] and variable burst release
rates (between 20% and 73%) with several drug–polymer combina-
tions [31,41,43] with use of these techniques have been reported.
The difference in the encapsulation and release pattern of AA and
A2P can be explained by the difference in their chemical structure.
Also the use of distiled water for AA release might have an impact
on these parameters as it is different from PBS in terms of pH and
ionic strength. However it was impossible for us to carry out a
release experiment of AA in PBS because the rapidly oxidising AA
reacted with the metal ions in PBS as soon as it was released. On
the other hand when AA was released in dH2O it was oxidising
with the oxygen in the air however this did not happen immedi-
ately (after 6 h in our experiments) allowing us to carry out the
experiment at 2 hourly intervals. The relative stability of AA at
pH: 7 in the absence of metal ions was previously demonstrated
[44]. Conclusively, we are demonstrating a reasonable encapsula-
tion efficiency of both AA and A2P and as expected A2P demon-
strates a more sustained release pattern compared to the release
of AA from the more hydrophilic AA scaffolds.
The next stage in the study was to culture fibroblasts on the
scaffolds and look at the effect of the ascorbic acid releasingength), Strain and YM (Young’s modulus)] (⁄⁄p < 0.005, ⁄p < 0.05 compared to vehicle
y 7 (n = 48) WET_day 14 (n = 48) WET_day 21 (n = 48)
Strain YM UTS Strain YM UTS Strain YM
0.77++ 24.06++ 2.36++ 0.73++ 13.57++ 2.26++ 0.59++ 21.78++,⁄
(0.08) (8.06) (0.44) (0.12) (4.70) (0.39) (0.17) (5.60)
0.44⁄⁄ 9.62+,⁄ 1.52++,⁄⁄ 0.37⁄⁄ 15.49++ 1.27++,⁄⁄ 0.31+,⁄⁄ 16.56++,⁄
(0.09) (7.03) (0.37) (0.18) (10.29) (0.46) (0.15) (12.75)
0.71+ 16.93++ 2.23++ 0.66+ 14.18++ 2.45++ 0.47++ 27.08++
(0.12) (6.51) (0.66) (0.17) (5.54) (0.35) (0.07) (4.56)
0.45 1.80 0.54 0.36 2.75 0.30 0.40 1.70
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Fig. 8. Production of ECM by human dermal fibroblasts grown on AA, A2P, Vehicle and PLA scaffolds for 14 days (A) Representative SEM images and corresponding DAPI
staining of the cell nuclei of fibroblasts, (B) total collagen production at day 14 as measured by Sirius Red staining [numbers after letters show grams of AA or A2P per gram of
PLA] and (C) metabolic activity over 14 days [n = 94; error bars show SEM; ⁄⁄p < 0.005 and ⁄p < 0.05 compared to Vehicle scaffolds; –p > 0.05].
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significant increase in collagen production in these cells when
grown on AA and A2P scaffolds.
Structurally we found that using the surfactant, Span80, to
produce emulsions within the scaffolds for AA, A2P and vehicle
controls did not affect the gross structure of the scaffolds as seen
in SEM images. However, there were effects of the surfactant
and of AA and A2P on the mechanical properties and water
absorptive capacity of the scaffolds. Surprisingly in the dry state
all emulsion electrospun scaffolds were stronger and more elas-
tic than non-loaded PLA scaffolds. These emulsion electrospun
scaffolds absorbed water gradually over several days and there
was a positive correlation between water uptake and the ulti-
mate tensile strength. This is almost certainly explained by the
plasticizing effect of water on PLA scaffolds [45]. Other surfac-
tants such as polyethylene glycol and glucose monoesters, has
previously been reported to act as a plasticisers [46]. AA scaf-
folds were more hydrophilic in the first 7 days (Fig. 6B) and
slightly but significantly stronger by day 7 (Table 1). This taken
together with the release of AA from the scaffolds, suggests a
contribution of AA to hydrophilicity and strength of these
scaffolds.
In other studies both AA and A2P have been shown to increase
ECM production of cells cultured on scaffolds in 3D [47–50] with
A2P being the more frequently used because of its greater stability.
To the best of our knowledge this is the first study to directly com-
pare scaffolds releasing AA and A2P for their effects on cells grown
on them. Interestingly the 3D results showed increased collagenproduction with increasing levels of A2P, as expected but with
the AA containing scaffolds the collagen production did not
increase with higher concentrations of AA. This is almost certainly
explained by the toxicity of AA at high concentrations in vitro that
might have occurred in the 3D microenvironment within the fibres
of the scaffold.
In conclusion, with respect to scaffold production this data con-
tributes to the literature by showing how incorporation of a deter-
gent can act as a plasticiser with changes in the mechanical
properties of the scaffolds. The incorporation of AA and A2P did
not weaken the scaffolds-indeed almost certainly because of the
incorporation of the detergent Span, these scaffolds were both
stronger and more elastic.
With respect to the usefulness of these materials for clinical use
we suggest that scaffolds releasing ascorbic acid could help the
integration of scaffolds into the pelvic floor by stimulating produc-
tion of adjacent tissues in the region. Also these scaffolds could be
introduced with cells in a tissue engineering approach and again
the scaffolds may stimulate new tissue production by the cells
on the scaffolds.
In developing materials for surgical treatment of POP and SUI it
is important to make materials that are biomechanically compati-
ble with the anatomical site of implantation [51,52]. The introduc-
tion of an ascorbic acid releasing scaffold that will stimulate new
collagen production and whose mechanical properties are not
compromised by the introduction of ascorbic acid is, we suggest,
a significant contribution to developing new materials for this
challenging site.
196 N. Mangır et al. / Acta Biomaterialia 29 (2016) 188–1975. Conclusion
It is possible to stimulate new collagen production by incorpo-
ration of both AA and A2P as emulsions into biocompatible,
biodegradable electrospun PLA scaffolds. Incorporation of these
forms of ascorbic acid actually increases the strength and elasticity
of scaffolds and may provide valuable new biomaterials for the
applications of the pelvic floor repair.
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